Oxidative damage and progression to Alzheimer's disease in patients with mild cognitive impairment

Journal of Alzheimer's Disease

Volumn 21, Issue 4, 2010, Pages 1165-1177

  Baldeiras, Inês ^a,b   Santana, Isabel ^a,b   Proença, Maria Teresa ^a,b   Garrucho, Maria Helena ^a,b   Pascoal, Rui ^a   Rodrigues, Ana ^a   Duro, Diana ^a   Oliveira, Catarina Resende ^a,b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Alzheimer's disease; antioxidants; longitudinal; mild cognitive impairment; oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; GLUTATHIONE; GLUTATHIONE DISULFIDE; LIPID; NITROGEN; PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CELLULAR DISTRIBUTION; COGNITION; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HOST RESISTANCE; HUMAN; LIPID PEROXIDATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 78650467580     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091723     Document Type: Article

References (72)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Gan-guli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus report. Lancet 366, 2112-2117.
2. Linn RT, Wolf PA, Bachman DL, Knoefel JE, Cobb JL, Be-langer AJ, Kaplan EF, D'Agostino RB (1995) The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort. Arch Neurol 52, 485-490.
3. Petersen RC, Doody R, Kurz QA, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 9581992.
4. Dawe B, Procter A, Philpot M (1992) Concepts of mild cognitive impairment in the elderly and their relationship to dementia: a review. Int J Geriatr Psychiatry 7, 473-479.
5. DeKosky ST, Marek K (2003) Looking backward to move forward: early detection of neurodegenerative disorders. Science 302, 830-834.
6. Lansbury Jr PT (2004) Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. Nat Med 10, S51-S57.
7. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, Capurso SA, Pietrarossa G, Santamato V, Capurso A, Panza F (2006) Circulating biomarkers of cognitive decline and dementia. Clin Chem Acta 364, 91-112. (Pubitemid 43120631)
8. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. JNeuropathol Exp Neurology 60, 759-767.
9. Moreira PI, Cardoso SM, Santos MS, Oliveira CR (2006) The key role of mitochondria in Alzheimer's disease. JAlzheimers Dis 9, 101-110.
10. Markerbery WR, Carney JM (1999) Oxidative alterations in Alzheimer's disease. Brain Pathol 9, 133-146.
11. Pratico D, Clark DM, Liun F, Lee V, Trojanowski JQ (2002) Increase of brain oxidative stress in mild cognitive impairment. A possible predictor of Alzheimer disease. Arch Neurol 59, 972-976.
12. Markesbery WR, Lovell MA (1998) 4-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19, 33-36.
13. Rinaldi P, Polidor MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senina U, Mecocci P (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24, 915-919.
14. Keller JN, Schmitt FA, Scheff SW, Ding P, Chen Q, Butterfield DA, Markesbery WR (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64, 1152-1156.
15. Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, Nucciarone B, Siciliano G (2005) Oxidative DNA damage in peripheral leukocytes ofmid cognitive impairment and AD patients. Neurobiol Aging 26, 567-573.
16. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, Venturelli E, Baron P, Bresolin N, Scarpini E (2006) Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 27, 262-269. (Pubitemid 43038550)
17. Greilberger J, Koldi C, Greilberger M, Lamprecht M, Schroechsnadel K, Leblhuber F, Fuchs D, Oettl K (2008) Mal-ondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res 42, 633-638.
18. Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, Ribera JM, Villar AM (2008) Peripheral levels of glu-tathione and protein oxidation as markers in the development of Alzheimer's disease and Mild cognitive impairment. Free RadicRes 42, 162-170.
19. Baldeiras I, Santana I, Proenca MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, Oliveira CR (2008) Peripheral oxidative damage in Mild Cognitive Impairment and mild Alzheimer's disease. J Alzheimers Dis 15, 117-128.
20. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (2001) Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1132-1142.
21. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. JPsychiat Res 12, 189-198.
22. Guerreiro M, Silva AP, Botelho MA (2003) Avaliacao Breve do Estado Mental: Escalas e Testes na Demencia. Grupo de Estudos de Envelhecimento Cerebral e Demencia, pp. 27-32.
23. Mohs RC, Rosen WG, Davis KL (1983) The Alzheimer's Disease Assessment Scale: an instrument for assessing treatment efficacy. Psychopharm Bull 19, 448-450
24. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's Disease. Am J Psychiatry 141, 1356-1364.
25. Guerreiro M, Fonseca S, Barreto J (2003) Escalas e Testes na Demencia. Grupo de Estudos de Envelhecimento Cerebral e Demencia, pp. 33-49.
26. Guerreiro (1988) Contribution of Neuropsychology to the Study of Dementias. Ph.D. thesis. Faculty of Medicine of Lisbon, Lisbon, Portugal.
27. Berg L (1988) Clinical dementia rating (CDR). Psychophar-macol Bull 24, 637-639.
28. Gelinas I, Gauthier L, McIntyre M, Gauthier S (1999) Development of a functional measure for persons with Alzheimer's Disease: The Disability Assessment For Dementia Scale. Am JOccupTher 53,471-481.
29. Leitao O (2008) Escalas e Testes na Demencia. Grupo de Estudos de Envelhecimento Cerebral e Demencia, pp. 107110.
30. Cummings JL (1997) The Neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 48, 10-16.
31. Leitao O, Nina A (2003) Escalas e Testes na Demencia. Grupo de Estudos de Envelhecimento Cerebral e Demencia, pp. 6786.
32. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Mas-deu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hof-man A, et al. (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, (4rd ed.), Washington, DC: American Psychiatric Association, 1994.
34. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical Diagnosis ofAlzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 4, 939-944.
35. Barham D, Trinder P (1972) An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst 97, 142-145.
36. Leenheer A, Bevere V, Claeys AE (1979) Measurement of a, ft, Y-tocopherol in serum by liquid chromatography. Clin Chem 25, 425-428.
37. Vatassery GT, Maynard UR, Hagen DF (1978) High-performance liquid chromatography of various tocopherols. J Chromatogr 161, 299-302.
38. Hissin PJ, Hilf R (1976) A Fluorimetric method for determination of oxidized and reduced gluthatione in tissues. Anal Biochem 74, 214-226.
39. Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization oferythrocyte gluthatione per-oxidase. J Lab Clin Med 70, 158-169.
40. Goldberg DM, Richard SJ (1983) Gluthatione reductase, in: Methods Enzymatic Analysis 3, Bergmeyer HO, ed., pp. 258265.
41. Draper HH, Hadley M (1990) Malondialdehyde determination as index of lipid peroxidation. Meth Enzymol 186, 421-431.
42. Punchard NA (1996) Free Radicals. A practical approach, Kelly FJ, ed., IRL Press Oxford, pp. 160-170.
43. Titheradge MA. The enzymatic measurement ofnitrate and nitrite. In Methods in Molecular Biology, Nitric oxide protocols, 100, Humana Press Inc., Totowa, NJ, pp. 83-91.
44. Crook R, Hardy J, Duff K (1994) Single-day apolipoprotein E genotyping. J Neurosci Methods 53, 125-127.
45. Guo S, ThompsonE(1992)PerformingtheexacttestofHardy-Weinberg proportion for multiple alleles. Biometrics 48, 361372.
46. Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ (2007) Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 68, 1588-1595.
47. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack Jr CR, Aisen PS, Thal LJ (2008) Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 70, 191-199.
48. Droge W, Schipper HM (2007) Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell 6, 361370.
49. Andriollo-Sanchez M, Hininger-Favier I, Meunier N, Ven-neria E, O'Connor JM, Maiani G, Coudray C, Roussel AM (2005) Age-related oxidative stress and antioxidant parameters in middle-aged and older European subjects: the ZENITH study. Eur J Clin Nutr 59, S58-62.
50. Rea IM, McMaster D, Donnelly J, McGrath LT, Young IS (2004) Malondialdehyde and measures of antioxidant activity in subjects from the Belfast Elderly Longitudinal Free-living Aging Study. Ann NY Acad Sci 1019, 392-395.
51. Gil L, Siems W, Mazurek B, Gross J, Schroeder P, Voss P, Grune T (2006) Age-associated analysis of oxidative stress parameters in human plasma and erythrocytes. Free Radic Res 40, 495-505.
52. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL (2003) Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108, 426-431.
53. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD (2008) Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71, 344-350.
54. Cangemi R, Loffredo L, Carnevale R, Perri L, Patrizi MP, San-guigni V, Pignatelli P, Violi F (2008) Early decrease of oxida-tive stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur Heart J 29, 54-62.
55. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17, 2653-2657.
56. Butterfield DA, Reed T, Perluigi M, de Marco C, Coccia R, Keller JN, Markesbery WR, Sultana R (2007) Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 1148, 243-248.
57. Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide and peorxynitrite: the good, the bad and ugly. Am J Physiol 271, C1424-C1437.
58. Zhu X, Smith MA, Honda K, Aliev G, Moreira PI, Nunomura A, Casadesus G, Harris PLR, Siedlak SL, Perry G (2007) Vascular oxidative stress in Alzheimer disease. J Neurol Sci 257, 240-246. (Pubitemid 46856513)
59. Selley ML (2003) Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 24, 903-907.
60. Corzo L, Zas R, Rodriguez S, Fernandez-Novoa L, Cacabelos R (2007) Decreased levels of serum nitric oxide in different forms of dementia. Neurosci Lett 420, 263-267.
61. Tarkowski E, Ringqvist A, Blennow K, Wallin A, Wennmalm I (2000) Intrathecal release of nitric oxide in Alzheimer's disease and vascular dementia. Dementia 11, 322-326.
62. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Yhibodeau SN, Kokmen E, Waring SC, Kurland LT (1995) Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 273, 1274-1278.
63. Fernandes MA, Proenca MT, Nogueira AJ, Grazina MM, Oliveira LM, Fernandes AI, Santiago B, Santana I, Oliveira CR (1999) Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients. Int JMol Med 4, 179-186.
64. Grodstein F, Chen J, Willet WC (2003) High-dose antioxidant supplements and cognitive function in community-dweling elderly women. Am J Clin Nutr 77, 3223-3229.
65. Engelhart MJ, Geerlinks MI, Ruitenberg A, vam Switen JC, Hofman A, Witteman JC, Breteler MM (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287, 3223-3229.
66. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer's transgenic mouse. J Neurosci 21, 8370-8377.
67. Conte V, Uryu K, Fujimoto S, Yao Y, Rokach J, Longhi L, Trojanowski JQ, Lee VM, McIntosh TK, Pratico D (2004) Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J Neurochem 90, 758-764.
68. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegi-line, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336, 1216-1222.
69. Le Bars PL, Velasco VM, Fergunson JM, Dessain EC, Keis-er M, Hoerr R (2002) Influence of the severity of cognitive impairment on the effect of Gingko biloba extract Egb 761 in Alzheimer's disease. Neuropsychobiology 45, 19-26.
70. Petersen RC, Thomas RG, Grundman M, Bennet D, Doody R, Ferris S, Galasko S, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment Alzheimer's Disease Cooperative Study Group. N Engl J Med 352, 2379-2388.
71. Pratico D (2008) Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy. Ann NY Acad Sci 1147, 70-78.
72. Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K (2008) Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimer Dis 15, 473-493.